IHS Headquarters, TBHCE and the IHS Vaccine Task Force Presents: COVID-19 Vaccine Update –
Recommendations, Safety and Effectiveness of COVID-19 Vaccine for Children Age 6 Months and Older

To Register: https://ihs-gov.zoomgov.com/webinar/register/WN_Yk5S0qLsS2Sbh0Q8DJYR6g

Date: Thursday, July 14, 2022│12:00 pm EST, 11:00 am CST, 10:00 am MST, 9:00 am PST, 8:00 am AKDT

Duration: 1 hour

 Panel Presenters:

• CAPT Holly Van Lew, PharmD, BCPS, AAHIVP, IHS COVID-19 Vaccine Task Deputy Lead
• Matthew Clark, MD, FACP, FAAP, IHS COVID-19 Vaccine Task Force Safety & Monitoring Team Lead
• CAPT Tom Faber, MD, MPH, FAAP, IHS Pediatrics Chief Clinical Consultant

Description:
The Indian Health Service COVID-19 Vaccine Task Force (VTF) continues to coordinate distribution of COVID-19 vaccines, monitor the COVID-19 landscape, and educate and inform stakeholders about COVID-19 vaccines authorized under an Emergency Use Authorization (EUA) or fully licensed by the Food and Drug Administration. COVID-19 vaccine recommendations continue to evolve and change, with expanded age authorizations, additional doses and booster dose recommendation expansions, expiration date extensions, safety announcements, and accumulation of real world and clinical trial safety and efficacy data. This webinar will inform healthcare team members at all levels about recent authorizations for pediatric children age 6 months and older, discuss future directions and highlight the complexities of the novel COVID-19 vaccines.

Outcomes/Objectives:

1. Describe the authorized dosing schedule, storage, handling, and administration recommendations for the Pfizer-BioNTech COVID-19 vaccine for children 6 months to 4 years, Moderna COVID-19 vaccine for children 6 months to 5 years, and Moderna COVID-19 vaccine for children 6-17 years.
2. Discuss the anticipated COVID-19 vaccine uptake for pediatric populations, work flow strategies, and  implementation considerations for vaccination in the pediatric population
3. Summarize available data on safety, effectiveness and adverse events for the Pfizer-BioNTech COVID-19 vaccine for children 6 months to 4 years and Moderna COVID-19 vaccine for children 6 months to 17 years.
4. Review vaccine safety monitoring systems in the Indian Health Service and logistics for VAERS reporting.

Target Audience: Physicians, Nurse Practitioners, Nurses, Pharmacists, Pharmacy Technicians, Physician Assistants, Social Workers, Psychologists, Immunization Coordinators, other members of the healthcare team, support staff or any employee or leader at I/T/U settings.

 There are no continuing education credits for this webinar